Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study

Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raderer M

Authors: Raderer M, Hörsch D, Lahner H, Rinke A, Denecke T,

Keywords: GEP-NET, Lanreotide, Temozolomide,

#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis

Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,

Keywords: Everolimus, progression-free survival, gastrointestinal NET,

#1211 Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment

Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kiesewetter B, Koparek O, Mayerhoefer M, Niederle B, Raderer M,

Keywords: GI-NEC,

#1194 Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study

Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: lanreotide, biomarker,

#1193 Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-) NETs: Post Hoc Analyses from the CLARINET Study

Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: lanreotide, quality of life,